This website uses cookies to enhance your browsing experience, improve site performance, and gather analytics. By selecting 'Accept,' you consent to these cookies as described in our Privacy Policy.

Logo

Neuroprotection During Open Heart Surgery

Sponsored by ghada fouad

About this trial

Last updated 6 years ago

Study ID

(MS/16.05.63)

Status

Completed

Type

Interventional

Phase

Phase 3

Placebo

No

Accepting

30 to 70 Years
All Sexes

Trial Timing

Ended 9 years ago

What is this trial about?

Millions of individuals with coronary artery, or valvular heart disease have been given a new chance at life by heart surgery, but the potential for neurological injury is a great risk .Neural complications - including neurocognitive dysfunction and ischemic complications are complications of cardiac surgery that can restrict the improved quality of life. Propofol is one of the most popular agents used for induction of anesthesia. propofol reduces cerebral blood flow but maintains coupling with cerebral metabolic rate for oxygen and decreases intracranial pressure, allowing optimal intraoperative conditions. Ketamine is a non-competitive antagonist of NMDA receptors that has well documented neuroprotective effects against ischemic brain injury and glutamate-induced brain injury. ketamine has neuroprotective effects against oxygen-glucose deprivation injury

What are the Participation Requirements?

Inclusion Criteria:Age between 30 and 70 years of either sex. * Patients scheduled for elective cardiac surgery using cardiopulmonary bypass (CPB) either valve surgery or coronary artery bypass surgery Exclusion Criteria: * Patient refusal. * Morbidly obese patients. * Patients with uncontrolled diabetes. * Patients with pre-existing neurological disease or using anti-psychotics. Severe or uncontrolled renal, hepatic or endocrinal diseases. * Pregnancy, post-partum or lactating females * Allergy to one of the agents used. * Emergency cardiac surgery. * Re-do surgery.